Trial Profile
Phase II/III study of MultiStem for the prevention and treatment of graft-versus-host disease in patients undergoing haematopoietic stem cell transplantation
Status:
Planning
Phase of Trial:
Phase II/III
Latest Information Update: 14 Mar 2016
Price :
$35
*
At a glance
- Drugs Invimestrocel (Primary)
- Indications Graft-versus-host disease
- Focus Therapeutic Use
- 10 Mar 2016 According to an Athersys company media release, this trial has received Special Protocol Assessment designation from the Food and Drug Administration and positive opinion from European Medicines Agency through its Scientific Advice procedure regarding the registration of this study.
- 13 Mar 2013 New trial record